Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13518597 | 0.98 | KDM4E (0.56) | KDM4EHSD11B1NCF1NPC1RAB9A | |
| SCHEMBL1703236 | 0.85 | PDGFRB (0.53) | KDM4EHSD11B1NPC1RAB9AALDH1A1 | |
| SCHEMBL1702107 | 0.81 | KDM4E (0.52) | KDM4EHSD11B1NCF1NPC1RAB9A | |
| SCHEMBL20913325 | 0.80 | TMPRSS4 (0.48) | KDM4EHSD11B1JAK2TRPV4TYK2 | |
| SCHEMBL25474482 | 0.79 | TRPV4 (0.39) | KDM4EHSD11B1ALDH1A1GAAJAK2 | |
| SCHEMBL1702910 | 0.78 | IDH1 (0.42) | KDM4EHSD11B1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1702420 | 0.78 | RAB9A (0.51) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10458402 | 0.78 | NCF1 (0.71) | KDM4ENCF1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30760998 | 0.78 | NCF1 (0.71) | KDM4ENCF1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1866621 | 0.78 | KDM1A (0.49) | KDM4EALDH1A1JAK2ABCG2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-3517534-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| EP-3521283-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | disclosed |
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2023-05-11 | — | — | US | disclosed |
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | disclosed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | disclosed |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
| WO-2021186053-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2021-09-23 | — | — | WO | disclosed |
| EP-3016656-B1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | ABIVAX (FR) | 2021-05-25 | — | — | US | disclosed |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | ABIVAX (FR) | 2021-05-25 | — | — | US | disclosed |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | ABIVAX (FR) | 2021-04-13 | — | — | US | disclosed |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | ABIVAX (FR) | 2021-04-13 | — | — | US | disclosed |
| WO-2020127853-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127843-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127839-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| EP-3669873-A1 | QUINOLINE DERIVATIVES FOR USE INE THE TRAEATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3669874-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3670659-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | ABIVAX (FR) | 2020-06-16 | — | — | US | disclosed |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | ABIVAX (FR) | 2020-06-16 | — | — | US | disclosed |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | ABIVAX (FR) | 2020-06-04 | — | — | US | disclosed |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | ABIVAX (FR) | 2020-06-04 | — | — | US | disclosed |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | ABIVAX (FR) | 2019-10-24 | — | — | US | disclosed |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | ABIVAX (FR) | 2019-10-24 | — | — | US | disclosed |
| EP-3521283-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521283-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | disclosed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | disclosed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2018-11-29 | — | — | US | disclosed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | disclosed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2440547-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | Société Splicos (FR) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885HSD11B1 65/4885NCF1 2297/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | KDM4E 3299/4885HSD11B1 168/4885NCF1 632/4885 |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR3C1, NR3C2 | KDM4E 3904/4885HSD11B1 82/4885NCF1 1539/4885 |
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ACE, ACE2, SARS1 | KDM4E 4678/4885HSD11B1 226/4885NCF1 1536/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | KDM4E 2650/4885HSD11B1 237/4885NCF1 717/4885 |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | TP53, BRCA1, LIMS1 | KDM4E 2378/4885HSD11B1 1604/4885NCF1 2955/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | CXCL8, FURIN, ABL1 | KDM4E 420/4885HSD11B1 1214/4885NCF1 1319/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | KDM4E 3886/4885HSD11B1 254/4885NCF1 2191/4885 |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | KDM4E 3841/4885HSD11B1 46/4885NCF1 759/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | KDM4E 3675/4885HSD11B1 634/4885NCF1 834/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885HSD11B1 65/4885NCF1 2297/4885 |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885HSD11B1 27/4885NCF1 1523/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | KDM4E 2880/4885HSD11B1 657/4885NCF1 731/4885 |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | TP53, BRCA1, LIMS1 | KDM4E 2378/4885HSD11B1 1604/4885NCF1 2955/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | KDM4E 3883/4885HSD11B1 62/4885NCF1 810/4885 |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | HAVCR2, CXCL8, IL36G | KDM4E 4712/4885HSD11B1 1821/4885NCF1 502/4885 |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | CXCL8, FURIN, ABL1 | KDM4E 420/4885HSD11B1 1214/4885NCF1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.